Predictive Diagnosis of Ulcero-Necrotizing EnteroColitis in Premature Babies Using an Artificial Intelligence Approach Based on Early Analysis of the Fecal Microbiota
NCT ID: NCT06727877
Last Updated: 2025-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1000 participants
INTERVENTIONAL
2025-04-01
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Its onset is unpredictable and sudden, usually between 10 and 20 days of life, and requires immediate, aggressive management: hemodynamic support, fasting, systemic antibiotic therapy or even surgery.
Prevention is therefore essential, but systematic measures with proven efficacy (breastfeeding, early enteral feeding, multiple probiotics) are few and far between. What's more, these preventive measures cannot be modulated and adapted individually, since it is not possible to finely predict the risk of developing enterocolitis.
Thus, the use of a predictive diagnostic test for NEC would make it possible to identify high-risk premature babies and develop personalized preventive measures.
Changes in the digestive microbiota precede the onset of NEC, but it has not been possible to identify a reproducible and reliable microbial signature. As a result, the limited power of microbiota analysis and interpretation means that it cannot be used in practice to predict ECUN.
Our partner team (MEDiS) has developed a bioinformatics chain (RiboTaxa) to obtain the precise structure of complex microbial communities from direct metagenomic sequencing data. Stool samples from international cohorts (1562 samples, 208 preterm infants) were then mined to train a deep neural network and generate a predictive diagnostic test for NEC. In a local study (10 cases and 10 controls), the predictive diagnostic performance of this test was 90%, with the 1ère stool identified as "at risk" preceding NEC by 8 days (extremes 4 - 17 days), and the 2nde by 2 days (extremes 0-7 days). We would now like to test our predictive diagnostic technique on a larger number of premature babies in the AURA region.
1000 children included, 200 children tested (50 NEC - 150 controls)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cohort of Premature Newborns for Charaterization of the Digestive Microbiota in Ulcerative Necrotizing Enterocolitis in Premature Infants
NCT04972734
Necrotizing Enterocolitis in Fetuses With Intrauterine Growth Restriction
NCT03869827
Risk Factors of Necrotizing Enterocolitis in Premature Newborns
NCT04719546
Defining the Intestinal Microbiota in Premature Neonates
NCT01102738
Use of Faecal Calprotectin to Predict Enteropathy of the Preterm Neonates
NCT02010268
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the event of discordant analysis between the 2 stools (approximately 35% of cases in our preliminary study), a 3ème stool will be analyzed in order to classify the child as being at risk of NEC or not. The person performing these analyses will not be informed of the child's clinical evolution.
The diagnosis of NEC will be made by the clinician in charge of the child, according to the Bell classification.
Follow-up until return home or transfer to a peripheral center. A telephone call will be made to parents at 3 months of age, to ensure that no NECN has occurred after transfer to a peripheral center.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NEC
diagnosis of NEC according to the Bell classification
Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.
The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.
The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns.
control
children without diagnosis of NEC
Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.
The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.
The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.
The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.
The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Child born outside CHU and transferred before 24h of life to the neonatal intensive care unit of one of thehospital participating in the study
* Affiliated with a Social Security scheme
Exclusion Criteria
* Children whose parents are under 18 years of age
* Refusal of parental authority to participate
1 Day
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maguelonne Pons
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
CHU Grenoble
Grenoble, , France
HFME
Lyon, , France
Hopital Croix Rousse
Lyon, , France
CHU Saint Etienne
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lise Laclautre
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A01840-47
Identifier Type: OTHER
Identifier Source: secondary_id
PHRC I 2023 PONS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.